Lupin Limited announced that it will pay Sunovion $75 million for the rights to Brovana arformoterol inhalation solution and Xopenex HFA levalbuterol MDI. Brovana has been approved in the US for the treatment of COPD since 2006, and Lupin launched an authorized generic of the inhalation solution in June 2021. Xopenex was initially approved for the treatment of asthma in 2005.
Over the past few years, Lupin has received FDA approval for a number of other generic inhalation products, including equivalents to Mylan’s Perforomist formoterol fumarate inhalation solution earlier this year; Teva’s ProAir HFA albuterol MDI in August 2020; and AstraZeneca’s Pulmicort Respules budesonide inhalation suspension in 2018 and Tobi tobramycin inhalation solution in 2017.
Lupin CEO Vinita Gupta commented, “We remain focused on strengthening our respiratory franchise in the US. We have established a strong position in the respiratory segment with our albuterol MDI and Brovana authorized generic launch. The addition of these two brands enhances our position in the segment.”
Read the Lupin press release.
